Phathom Pharmaceuticals Inc — Cash Flow (NASDAQ:PHAT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -69.69 M-148.62 M-146.53 M-137.58 M-266.77 M-166.78 M -166.78 M Cash from investing activities -1.04 M-328 K-1.04 M-1.63 M-135 K-229 K -229 K Cash from financing activities 114.46 M44.71 M120.04 M367.58 M182.77 M-288 K -288 K Free cash flow -70.73 M-148.94 M-147.57 M-139.21 M-266.9 M-167 M -167 M

News

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Stifel reiterates Buy on Phathom stock, keeps $28 price target

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates

Phathom Q4 2025 slides: 217% revenue growth, profitability in sight

Phathom Pharma earnings beat by $0.34, revenue topped estimates